Epigenetics in Drug Discovery
News Jan 07, 2016
Chromatrap®, a business unit of Porvair Sciences, has announced that it will be the Lead Sponsor at the prestigious “Epigenetics in Drug Discovery” conference to be held in Cambridge, UK from 26th-27th January 2016.
Viewed as a new frontier in drug discovery, rapid progress has been made in enhancing understanding of epigenetic mechanisms of both new and existing drugs. With the processes that control epigenomic function providing new opportunities, epigenetics targets are enabling the discovery of novel drugs.
At the conference - Dr Amy Beynon will deliver a presentation highlighting the use of new Chromatrap solid state ChIP technology for assaying methylated and hydroxymethylated DNA marks in addition to Histone modifications and the use of Chromatrap kits for ChIP-sequencing.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.